John Taylor has joined Ribocure Pharmaceuticals AB as Vice President and Head of Global Business Development. John will lead the global BD team and oversee partnering discussions for Ribocure Pharmaceuticals AB, as well as its parent company Ribo Life Sciences (Ribo) to support its externalization.
Li Ming Gan, Ribocure’s CEO and Co-CEO for Ribo said: “We are pleased to welcome a BD leader of John’s caliber to our executive team. With a distinguished career spanning over more than two and a half decades in the global pharmaceutical and biotech industry, his breadth of experience and demonstrated expertise in business development, innovative R&D, and scientific affairs will be a significant asset to our organization.”
John Taylor stated, “I am thrilled to be joining Ribocure and I am inspired by Ribocure’s purpose and strategy to drive new, innovative siRNA development from target discovery to treatments. I am looking forward to work with the extended Ribocure and Ribo teams to drive business development aiming for productive collaborations for the benefit of patients.”
Key Biographical Details
John has experience in Business Development having worked in Transactions and Search and Evaluation within Business Development for AstraZeneca. Before this he worked in AZ Lund as a Biology Department Head. John previously worked for Pfizer Global Research and Development in Sandwich U.K. Overall John has over 25 years’ experience of the pharmaceutical and biotech industry. John’s academic training was completed at Bristol University in the UK and Duke University in the USA.
John will be based in Gothenburg Sweden and can be contacted on the email John.Taylor@Ribocure.com regarding partnering opportunities.
About Ribocure and Ribo Life Sciences
Ribocure Pharmaceuticals AB (Ribocure) is a biotech company based in Sweden, dedicated to advancing the field of cutting-edge RNA therapeutics. Ribocure’s mission is to establish a world-leading company in RNA research and development, ultimately making a positive impact on patients worldwide.
Ribo Life Science Co., Ltd. (Ribo) is located at three major sites in China. Based on its cutting edge RNAi technologies, Ribo has established oligonucleotide therapeutic platform that vertically integrates the complete set of technologies to support the full life cycle of oligonucleotide therapeutics from early R&D to commercialization and commercial production. Ribo/Ribocures portfolio includes several projects in the clinical stage, which have documented Best In Class (BIC) properties. The portfolio includes projects in several different disease areas, including cardio-metabolic, liver, rare and ocular diseases.
